NCT02630290View on ClinicalTrials.gov

Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial)

PHASE4CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2015

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Radius FracturesUlna FracturesHand InjuriesWrist InjuriesForearm Injuries
Interventions
DRUG

Ropivacaine

Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine

DRUG

Ropivacaine + Dexmedetomidine

Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine

Trial Locations (1)

020

Guangzhou First Municipal People's Hospital, Guangzhou

All Listed Sponsors
lead

Guangzhou First People's Hospital

OTHER

NCT02630290 - Addition of Dexmedetomidine to Ropivacaine-induced Supraclavicular Block (ADRIB Trial) | Biotech Hunter | Biotech Hunter